FDA Seeks Input on Renewing Generic Drug Fees Through 2032
Published Date: 8/11/2026
Notice
Summary
The Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting to discuss proposed recommendations for the reauthorization of the Generic Drug User Fee Amendments (GDUFA) for fiscal years (FYs) 2028 to 2032. GDUFA amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) to authorize FDA to assess and collect fees to support human generic drug activities. The current legislative authority for GDUFA expires at the end of September 2027. At that time, new legislation will be required for FDA to continue to assess and collect generic drug user fees for future fiscal years. The FD&C Act directs FDA, following negotiations with the regulated industry and periodic consultations with other stakeholders, to present recommendations for reauthorization of the GDUFA program to the relevant Congressional committees, publish the recommendations in the Federal Register, provide for a period of 30 days for the public to provide written comments on such recommendations, and hold a meeting at which the public may present its views on such recommendations. FDA will then consider such public views and comments and revise such recommendations as necessary.
Analyzed Economic Effects
8 provisions identified: 6 benefits, 1 costs, 1 mixed.
Foreign Facility Fee Jump to $25,000
FDA proposes to increase the foreign fee differential from $15,000 to $25,000 starting in FY 2028 for all foreign API, finished dosage form (FDF), and contract manufacturing organization (CMO) facilities. If adopted, companies using foreign facilities would face an additional $10,000 fee per affected facility beginning in FY 2028.
One-Time ANDA Fee Waiver for U.S.-Only Applicants
FDA proposes a one-time waiver of the original ANDA application fee if an applicant’s submission identifies only U.S.-located FDF manufacturers and U.S.-located API suppliers. This waiver would apply to qualifying domestic applicants for an original ANDA submission under the proposed GDUFA IV terms.
Shift in Fee Revenue Allocation (26% ANDA Share)
FDA proposes changing the statutory allocation so ANDA submission fees would make up 26% of total GDUFA fee revenues (down from 33%), with the difference shifted to program fees. This is a statutory reallocation of how fee revenue is sourced under GDUFA IV.
Expanded DMF Prior-Assessment Eligibility
FDA proposes expanding DMF prior-assessment eligibility to include complex APIs, prior approval supplements adding a new U.S. API source, and certain DMF requests related to ANDAs submitted near the RLD patent/exclusivity expiry date. This broadens what types of DMF requests may receive prior assessments.
New ANDA Review Timeline Options and Extensions
FDA proposes review-process changes including a new 120-day goal extension option for certain pOAI alerts, a new 6‑month re-assigned goal date for complex data issues (with a meeting offer if missed), and a post pre-approval inspection meeting option. Applicants may also select a goal-date extension at submission time.
Advance Inspection Requests for U.S. Facilities
FDA proposes to let existing U.S. generic API and FDF facilities without recent inspection history request an inspection in advance of a planned DMF or ANDA submission that will include the facility. This gives such U.S. facilities an opportunity to obtain inspections ahead of submitting regulatory files.
Public Maximum Daily Dose (MDD) Database
FDA proposes to establish a public Maximum Daily Dose (MDD) database populated with at least 500 MDD values for reference listed drugs (RLDs) by the end of FY 2028, and to continue adding values thereafter. FDA will also seek public input on the database's utility.
Inactive Ingredient Database (IID) Updates and MDE Transition
FDA proposes to continue updating the Inactive Ingredient Database (IID) on an ongoing basis, post quarterly notices of updates, add ingredients newly and accurately identified in labeling approved on or after October 1, 2027, and continue the IID transition from maximum potency to maximum daily exposure (MDE) information.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16420, Guide To Minimize Biological Hazards in Ready-to-Eat Fresh-Cut Produce; Guidance for Industry; Availability
The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for industry entitled "Guide to Minimize Biological Hazards in Ready-to-Eat Fresh-Cut Produce." This guidance supersedes a previous guidance, entitled "Guide to Minimize Microbial Food Safety Hazards of Fresh-Cut Fruits and Vegetables," issued in 2008, and is a final guidance to the draft guidance for industry entitled "Guide to Minimize Food Safety Hazards of Fresh-Cut Produce" issued in 2018. The guidance is intended to help manufacturers or processors of ready-to-eat fresh-cut produce that is not a low-moisture food comply with applicable requirements in our regulations on current good manufacturing practices for hazard analysis and risk-based preventive controls for human food.
2026-16248, Determination That OZOBAX (Baclofen) Oral Solution, 5 Milligrams/5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that OZOBAX (baclofen) oral solution, 5 milligrams (mg)/5 milliliters (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
2026-16209, Radiology Devices; Reclassification of Digital Breast Tomosynthesis System
The FDA wants to change how digital breast tomosynthesis (DBT) systems are classified, moving them from a strict, high-level category (Class III) to a more flexible one (Class II) with special safety rules. This affects companies making these breast imaging devices, making it easier and faster to get them approved. Comments on this change are open until October 9, 2026, so stakeholders should act fast to share their thoughts!
Previous / Next Documents
Previous: 2026-16352, Agency Information Collection Activities: Submission for OMB Review; Comment Request
We have submitted a request to the Office of Management and Budget (OMB) for approval to continue to use two information collections. The first information collection is prepared by companies and organizations to request to digitize archival holdings with privately-owned equipment. The second information collection is used when veterans, dependents, and other authorized individuals request information from or copies of documents in military personnel, military medical, and dependent medical records. We invite you to comment on the proposed information collections. There have been no changes made to these collections.
Next: 2026-16355, Foreign-Trade Zone (FTZ) 153; Withdrawal of Notification of Proposed Production Activity; Foxx Development, Inc.; (Production of Smartphones); San Diego, California